Chronic obstructive pulmonary disease (COPD)

• COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients Pending
  2024-519163-18-00 6
• A Study to evaluate the long-term safety and tolerability of tozorakimab in patients with chronic obstructive pulmonary disease (COPD) and a … Recruiting
  2025-523690-41-00 5 2026-05-04
• Exploring the anti-aging effects of Metformin in COPD Recruiting
  2025-520972-24-00 5 2026-04-08
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona … Recruiting
  2024-517458-90-00 5 2025-06-06
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona … Recruiting
  2024-517457-27-00 5 2025-06-04
• Molecular signatures associated with response to ICS treatment in patients with COPD stratified by eosinophil levels Recruiting
  2023-505245-13-00 6 2025-02-12
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04
• Clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Recruitment ended
  2024-516714-37-00 5 2022-01-19
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12
• An open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the e … Ended
  2023-506345-34-00 3 2023-10-23
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20
• COPD - Eosinophil-guided Reduction of Inhaled Corticosteroids (COPERNICOS) Ended
  2022-501035-16-01 6 2022-08-23
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153 … Ended
  2023-510172-31-00 5 2022-04-22
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503572-24-00 5 2022-03-02
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-507093-40-00 4 2022-01-27
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503571-19-00 5 2022-01-20
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 5 2021-06-17
• TRACkER trial Ended
  2023-508300-37-00 6

Showing 1–19 of 19 trials